 CAMBRIDGE, Mass.--BUSINESS WIRE--Alnylam Pharmaceuticals, Inc. Nasdaq: ALNY, the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 HAO1 the gene encoding glycolate oxidase GO for the treatment of primary hyperoxaluria type 1 PH1. These data were presented at the American Society of Pediatric Nephro 